Investor And Media

Presentations and events

 

Presentation vid Stockholm Corporate Finance Life Science Seminarium

22 mars 2017

[SE PRESENTATION]

 

Presentation vid Investor Dagen i Köpenhamn

21 mars 2017

[SE PRESENTATION]

 

Presentation vid Biotech Showcase i San Francisco 

11 januari 2017  

[SE PRESENTATION]

 

Aktiespararna Stockholm Vasa och Financial Stockholm

25 oktober kl. 18:00

[SE PRESENTATION]

 

Aktiespararna, Malmö Centrum

May 11th, 2016

 

Interview with CEO Henrik Lawaetz

March 16th, 2016

[WATCH INTERVIEW]

 

Sedermeradagen, Lund

March 16th, 2016

 

Stockholm Corporate Finance, Stockholm

March 10th, 2016

Video from presentation of WntResearch at Stockholm Corporate Finance

CEO Henrik Lawaetz and CSO Tommy Andersson presented the company  at Stockholm Corporate Finance Life Science & Healthcare Seminar at Operaterrassen in Stockholm Thursday March 10th.

[VIEW VIDEO]

 

LifeScienceDagen 2016, Göteborg.

 March 9th, 2016

 

A commentary on the interim Foxy-5 phase 1 study report

The recent publication of an interim report of Foxy-5 clinical Phase 1 study has raised a lot of questions. This has prompted us to write a clarification on how WntResearch values the results obtained so far.

[VIEW COMMENTARY]

 

Short congress report 

From AACR.NCI.EORTC Scientific meeting: Molecular Targets and Cancer Therapeutics in cancer, November 5-9, 2015 in Boston, USA with comments from CEO Nils Brünner

[VIEW REPORT]

 

Foxy-5 - Preliminary Report: Phase I

Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate Cancer
November 6th, 2015

[VIEW REPORT]

 

WntResearch at Sedermeradagen in Lund 26 March 2015

Speaker: Nils Brünner, VD

[VIEW PRESENTATION]

 

Annual General Assembly, Malmø, 09.06.15

Speaker: Nils Brünner, CEO

[VIEW PRESENTATION]